A research team from the University of Nebraska Medical Center (UNMC; NE, USA) led by Benson Edagwa (Assistant Professor) and Howard Gendelman (Chairman and Professor) have developed a potential novel therapeutic for the prevention of HIV infection. The team have discovered a way to administer antiretrovirals (ARVs) that patients take daily to control the disease, to just a once-a-year vaccine dose instead. “This pharmaceutical development has the potential to not only treat but also prevent viral transmission,” stated Gendelman. “This may certainly be a therapeutic milestone.” The year-long acting drug is based on the existing drug cabotegravir (CAB), which blocks...
To view this content, please register now for access
Join our member community for FREE to access a collection of journal and online-only features, including:
- Exclusive access to educational videos, eBooks and insights into top BioTechniques journal articles
- The latest news and journal updates delivered straight to your inbox when you want it
- Personalized recommendations for the latest member-exclusive podcasts, interviews and expert opinions
- Priority registration to webinars, panel discussions and events
- Access to competitions and journal publication discounts, including 10% off open access fees when you sign up today!